
Operations Office

Telephone (507) 266-3549



Date: May 26, 2006

To: NCCTG Members

From: Lori Bratvold
Protocol Development Coordinator

Re: N0177, A Phase I/II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Attached is a revised Evaluation/Treatment form. Footnote * has been revised for clarification. Please replace your current version with this revised version.

If you have any questions concerning this communication, please contact me at 507/266-3549.

Thank you.

LB
enclosure